Department of Ophthalmology, LinYi Central Hospital, Linyi, Shandong, China (mainland).
Department of Clinical Laboratory, Jining No.1 People's Hospital, Jining, Shandong, China (mainland).
Med Sci Monit. 2019 Apr 30;25:3190-3198. doi: 10.12659/MSM.914074.
BACKGROUND Uveal melanoma (UM) is the most common intraocular malignancy, and the prognosis of patients with advanced stage of UM is very dismal. The T cell receptor ectopic expression of butyrophilin-like 9 (BTNL9) has been observed in several types of cancers, but the expression and clinical significance of BTNL9 in UM is unclear. MATERIAL AND METHODS In our study, we detected the expression of BTNL9 in 6 pairs of UM tissues and adjacent tissues using quantitative real-time polymerase chain reaction (qRT-PCR), and further investigated BTNL9 expression with immunohistochemistry (IHC) in a retrospective cohort consisted of 62 UM patients. The correlations between BNTL9 expression and clinicopathological factors were analyzed with Fisher's test, and the prognostic significance of BTNL9 was evaluated with univariate analysis and multivariate analysis. Using experiments in vitro, we investigated the function of BTNL9 in UM proliferation and invasion. RESULTS BTNL9 mRNAs in adjacent tissues were remarkably higher than in UM tissues. The percentages of BTNL9 low expression and high expression were 56.45% and 43.55%, respectively. High expression of BTNL9 was significantly associated with favorable prognosis of UM. BTNL9 expression was identified as a prognostic biomarker predicting better outcome of UM patients. Moreover, BTNL9 could suppress invasion instead of proliferation in melanoma cell line. CONCLUSIONS BTNL9 was a favorable prognostic factor of UM and it could suppress invasion of UM, suggesting that BTNL9 detection could help stratify high-risk patients with UM after operation and guide more precise surveillance and treatment.
葡萄膜黑色素瘤(UM)是最常见的眼内恶性肿瘤,晚期 UM 患者的预后非常差。在几种类型的癌症中已经观察到丁酰膦蛋白样 9(BTNL9)的 T 细胞受体异位表达,但 BTNL9 在 UM 中的表达和临床意义尚不清楚。
在我们的研究中,我们使用实时定量聚合酶链反应(qRT-PCR)检测了 6 对 UM 组织和相邻组织中 BTNL9 的表达,并进一步使用免疫组织化学(IHC)在 62 例 UM 患者的回顾性队列中研究了 BTNL9 的表达。采用 Fisher 检验分析 BTNL9 表达与临床病理因素的相关性,采用单因素和多因素分析评估 BTNL9 的预后意义。通过体外实验,我们研究了 BTNL9 在 UM 增殖和侵袭中的作用。
相邻组织中的 BTNL9 mRNAs 明显高于 UM 组织。BTNL9 低表达和高表达的百分比分别为 56.45%和 43.55%。BTNL9 高表达与 UM 的良好预后显著相关。BTNL9 表达被确定为预测 UM 患者预后更好的预后生物标志物。此外,BTNL9 可以抑制黑色素瘤细胞系的侵袭,而不是增殖。
BTNL9 是 UM 的一个有利的预后因素,它可以抑制 UM 的侵袭,这表明 BTNL9 的检测可以帮助在手术后对 UM 高危患者进行分层,并指导更精确的监测和治疗。